COVID-19-Induced Modifications in the Tumor Microenvironment: Do They Affect Cancer Reawakening and Metastatic Relapse?
cancer
coronavirus disease 2019
disseminated tumor cells
dormancy
inflammation
relapse
tumor microenvironment
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2020
2020
Historique:
received:
08
08
2020
accepted:
07
10
2020
entrez:
16
11
2020
pubmed:
17
11
2020
medline:
17
11
2020
Statut:
epublish
Résumé
Severe coronavirus disease 2019 (COVID-19) causes an uncontrolled activation of the innate immune response, resulting in acute respiratory distress syndrome and systemic inflammation. The effects of COVID-19-induced inflammation on cancer cells and their microenvironment are yet to be elucidated. Here, we formulate the hypothesis that COVID-19-associated inflammation may generate a microenvironment favorable to tumor cell proliferation and particularly to the reawakening of dormant cancer cells (DCCs). DCCs often survive treatment of primary tumors and populate premetastatic niches in the lungs and other organs, retaining the potential for metastatic outgrowth. DCCs reawakening may be promoted by several events associated to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, including activation of neutrophils and monocytes/macrophages, lymphopenia and an uncontrolled production of pro-inflammatory cytokines. Among pro-inflammatory factors produced during COVID-19, neutrophil extracellular traps (NETs) released by activated neutrophils have been specifically shown to activate premetastatic cancer cells disseminated in the lungs, suggesting they may be involved in DCCs reawakening in COVID-19 patients. If confirmed by further studies, the links between COVID-19, DCCs reactivation and tumor relapse may support the use of specific anti-inflammatory and anti-metastatic therapies in patients with COVID-19 and an active or previous cancer.
Identifiants
pubmed: 33194755
doi: 10.3389/fonc.2020.592891
pmc: PMC7649335
doi:
Types de publication
Journal Article
Langues
eng
Pagination
592891Informations de copyright
Copyright © 2020 Francescangeli, De Angelis, Baiocchi, Rossi, Biffoni and Zeuner.
Références
Clin Cancer Res. 2010 Feb 1;16(3):1008-15
pubmed: 20103685
Nat Rev Immunol. 2020 Jun;20(6):355-362
pubmed: 32376901
Lancet Oncol. 2020 Oct;21(10):1309-1316
pubmed: 32853557
Nat Rev Cancer. 2020 Jul;20(7):398-411
pubmed: 32488200
Nature. 2019 Aug;572(7770):538-542
pubmed: 31367040
Oncogene. 2018 May;37(22):2903-2920
pubmed: 29515232
Cancer Res. 2011 Sep 1;71(17):5688-96
pubmed: 21784871
Science. 2018 Sep 28;361(6409):
pubmed: 30262472
J Exp Clin Cancer Res. 2019 Apr 25;38(1):173
pubmed: 31023337
Molecules. 2020 Apr 01;25(7):
pubmed: 32244751
Clin Cancer Res. 2015 Jan 1;21(1):201-10
pubmed: 25564572
Front Cell Infect Microbiol. 2020 Jun 12;10:340
pubmed: 32596170
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
Nature. 2019 Mar;567(7747):249-252
pubmed: 30842658
Proc Natl Acad Sci U S A. 2015 Dec 29;112(52):16000-5
pubmed: 26668367
Mol Immunol. 2019 Jun;110:69-76
pubmed: 29269005
Immunity. 2019 Apr 16;50(4):1007-1023
pubmed: 30995492
Blood. 2020 Sep 3;136(10):1169-1179
pubmed: 32597954
Int J Mol Sci. 2018 Jul 24;19(8):
pubmed: 30042333
Int J Oncol. 2020 Feb;56(2):596-605
pubmed: 31894273
Crit Rev Oncog. 2013;18(1-2):43-73
pubmed: 23237552
Nat Rev Cancer. 2015 Apr;15(4):238-47
pubmed: 25801619
Exp Oncol. 2013 Dec;35(4):295-302
pubmed: 24382441
JCI Insight. 2018 Aug 23;3(16):
pubmed: 30135299
Cancer Lett. 2016 Jul 1;376(2):268-77
pubmed: 27063099
Cancer Res. 2014 Apr 1;74(7):1958-68
pubmed: 24531750
Eur J Cancer. 2020 Nov;139:43-50
pubmed: 32971510
Cell. 2016 Mar 24;165(1):45-60
pubmed: 27015306
J Clin Invest. 2019 Jul 15;129(8):3324-3338
pubmed: 31305264
J Exp Med. 2020 Dec 7;217(12):
pubmed: 32926097
Front Cell Dev Biol. 2020 Mar 18;8:166
pubmed: 32258040
Nat Cell Biol. 2017 Aug;19(8):974-987
pubmed: 28737771
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Nat Rev Immunol. 2018 Dec;18(12):773-789
pubmed: 30254251
Nat Rev Clin Oncol. 2018 Apr;15(4):205-218
pubmed: 29283170
Nat Rev Microbiol. 2009 Mar;7(3):226-36
pubmed: 19198616
Oncogene. 2009 Aug 20;28(33):2940-7
pubmed: 19581928
Cancer Discov. 2020 Jul;10(7):916-921
pubmed: 32444466
Lancet. 2020 Jun 20;395(10241):1907-1918
pubmed: 32473681
J Physiol Sci. 2019 Jul;69(4):581-587
pubmed: 31028527
Lancet. 2020 Jul 4;396(10243):27-38
pubmed: 32479829
Nat Rev Immunol. 2020 Sep;20(9):529-536
pubmed: 32728222
Oncotarget. 2018 Apr 3;9(25):17543-17553
pubmed: 29707128
Cancer Res. 2014 Jan 1;74(1):8-14
pubmed: 24362915
JCI Insight. 2018 Dec 6;3(23):
pubmed: 30518684
J Exp Med. 2020 Dec 7;217(12):
pubmed: 32926098
Immunity. 2020 Jun 16;52(6):910-941
pubmed: 32505227
J Clin Invest. 2010 Jun;120(6):2030-9
pubmed: 20501944
Br J Haematol. 2020 Jul;190(2):e73-e76
pubmed: 32433778
J Exp Clin Cancer Res. 2016 Feb 04;35:27
pubmed: 26847351
Clin Cancer Res. 2013 Sep 1;19(17):4706-16
pubmed: 23690484
Sci Rep. 2018 Aug 1;8(1):11573
pubmed: 30069023
Oncol Rep. 2010 Apr;23(4):941-8
pubmed: 20204277
Oncoimmunology. 2016 Oct 20;5(12):e1247135
pubmed: 28123883
Cancer Res. 2012 Feb 15;72(4):865-75
pubmed: 22194466
Clin Immunol. 2020 Sep;218:108517
pubmed: 32585295
Immunity. 2019 Apr 16;50(4):812-831
pubmed: 30995501
Immunity. 2020 May 19;52(5):731-733
pubmed: 32325025
Nat Rev Microbiol. 2016 Aug;14(8):523-34
pubmed: 27344959
Immunity. 2020 May 19;52(5):856-871.e8
pubmed: 32289253
J Immunol. 2020 Sep 1;205(5):1198-1206
pubmed: 32680957
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Autoimmun Rev. 2020 Jun;19(6):102536
pubmed: 32251718
Oncogene. 2019 Jun;38(25):4932-4947
pubmed: 30804456
Lancet Oncol. 2020 Jul;21(7):914-922
pubmed: 32539942
Cancer Res. 2016 Dec 1;76(23):6778-6784
pubmed: 27530323
Immunol Rev. 2018 Jan;281(1):57-61
pubmed: 29247996
Neoplasia. 2016 May;18(5):273-281
pubmed: 27237319
Nat Rev Immunol. 2018 May;18(5):309-324
pubmed: 29379212
J Exp Clin Cancer Res. 2019 Nov 26;38(1):474
pubmed: 31771617
J Clin Invest. 2013 Jul 1;:
pubmed: 23863628
JCI Insight. 2020 Jun 4;5(11):
pubmed: 32329756
Oncogene. 2019 May;38(20):3765-3780
pubmed: 30262865
Nat Med. 2020 Aug;26(8):1218-1223
pubmed: 32581323
EBioMedicine. 2020 May;55:102763
pubmed: 32361250
Nat Cell Biol. 2018 Nov;20(11):1240-1249
pubmed: 30361702
Cell. 2020 Oct 1;183(1):4-10
pubmed: 32979319
Nat Commun. 2017 Nov 10;8(1):1404
pubmed: 29123081
Rheumatology (Oxford). 2015 Apr;54(4):736-42
pubmed: 25252703
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Cell. 2010 Mar 19;140(6):883-99
pubmed: 20303878
Nature. 2019 Mar;567(7749):540-544
pubmed: 30867597
Semin Immunol. 2014 Feb;26(1):38-47
pubmed: 24602448
N Engl J Med. 2020 Jul 17;:
pubmed: 32678530
EMBO Mol Med. 2020 Aug 7;12(8):e12697
pubmed: 32473600
J Exp Med. 2020 Jun 1;217(6):
pubmed: 32302401
Nat Commun. 2018 Sep 28;9(1):3996
pubmed: 30266897
Lancet Rheumatol. 2020 Jun;2(6):e325-e331
pubmed: 32501454
J Immunol. 2015 Nov 1;195(9):4319-30
pubmed: 26401005